Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology
Authors:
- 1 February 2010
- journal article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 32 (1p2) , 95-102
Abstract
Summary: The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). We found plasma levels of total JAK2 mRNA to be higher in patients with non‐CML MPD (n = 175) than in CML patients (n = 45) and normal controls (n = 58) (each P < 0.001). Overall survival was studied in 68 patients and showed positive correlation with levels of total and mutant JAK2 mRNA in patients with the V617F mutation, but not those without the mutation. These findings suggest that total JAK2 expression levels play a role in the biology of the disease in V617F‐positive patients, and a therapy aiming at downmodulating the expression of the total JAK2 mRNA should be considered. In conclusion, we studied JAK2 total and V6217F mutant mRNA levels in plasma. We show high levels of JAK2 expression in MPD patients and these levels correlate with survival.Keywords
This publication has 18 references indexed in Scilit:
- Higher detection rate of JAK2 mutation using plasmaBlood, 2008
- JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosisHaematologica, 2007
- Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemiaHaematologica, 2007
- Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviourBritish Journal of Haematology, 2006
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significanceBlood, 2003